[18F]fluoro-2-deoxy-D-glucose + [18F]dihydro-testosterone

This is a combination of two radiopharmaceuticals used in positron emission tomography (PET) imaging: - **[18F]fluoro-2-deoxy-D-glucose ([18F]FDG):** A glucose analog labeled with the positron-emitting isotope fluorine-18. It is taken up by cells via glucose transporters and phosphorylated by hexokinase but cannot undergo further metabolism, resulting in intracellular trapping. This property allows for imaging of tissues with high glycolytic activity, such as most malignant tumors. It is widely used for cancer diagnosis, staging, restaging, and monitoring response to therapy[1][6][10]. - **[18F]dihydro-testosterone ([18F]FDHT):** A radiolabeled structural analog of dihydrotestosterone that binds selectively to androgen receptors (AR). It enables noninvasive PET imaging of AR expression in vivo and is particularly useful for detecting metastatic or recurrent prostate cancer lesions due to their AR positivity. It has also been studied in other hormone-driven cancers such as breast cancer[1][2][4][5]. The combination allows simultaneous or sequential assessment of tumor metabolic activity (via glucose uptake) and androgen receptor status within the same patient using PET/CT imaging protocols.

Other names

FDG + FDHTF-18 FDG + F-18 FDHT